This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Renal Cell Carcinoma Urothelial cancer
Renal Cell Carcinoma Urothelial cancer
Advanced MelanomaAdjuvant Melanoma
Adjuvant esophageal (EC or GEJC) 1L adenocarcinoma upper GI 1L or 2L esophageal squamous cell carcinoma (ESCC)
Head & Neck
Hodgkin Lymphoma

Adjuvant esophageal (EC or GEJC)

OPDIVO, THE ONLY IMMUNOTHERAPY AVAILABLE ACROSS ALL LINES AND HISTOLOGIES OF UPPER GI PATIENTS

View indication details

    Adjuvant treatment
  • OPDIVO as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.
    • First-line treatment (Please note, as from the 1st of September 2023, OPDIVO is no longer reimbursable as a first-line treatment if the patient has progressed on a previous line of checkpoint inhibitor.)
  • OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.
  • OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.
  • OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.Please note, this indication is not reimbursed in Belgium.
    • Second line or + treatment
  • OPDIVO as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.

OPDIVO as monotherapy is indicated and reimbursed for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

OPDIVO as monotherapy is indicated and reimbursed for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

OPDIVO as monotherapy is indicated and reimbursed for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated and reimbursed for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%. Please note, as from 1st September 2023, OPDIVO is no longer reimbursable as 1L treatment if the patient has progressed on a previous line of checkpoint inhibitor

OPDIVO in combination with fluoropyrimidine and platinum-based combination chemo-therapy is indicated and reimbursed for the first-line treatment of adult patients with HER2‑negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5. Please note, as from 1st September 2023, OPDIVO is no longer reimbursable as 1L treatment if the patient has progressed on a previous line of checkpoint inhibitor

OPDIVO in combination with fluoropyrimidine and platinum-based combination chemo-therapy is indicated and reimbursed for the first-line treatment of adult patients with HER2‑negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5. Please note, as from 1st September 2023, OPDIVO is no longer reimbursable as 1L treatment if the patient has progressed on a previous line of checkpoint inhibitor

OPDIVO in combination with fluoropyrimidine and platinum-based combination chemo-therapy is indicated and reimbursed for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5. Please note, as from 1st September 2023, OPDIVO is no longer reimbursable as 1L treatment if the patient has progressed on a previous line of checkpoint inhibitor

OPDIVO as monotherapy is indicated and reimbursed for the treatment of adult patients with unresectable advanced, recurrent or meta-static oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.

Expert opinion

CheckMate 649
5-year update

recommendations
in upper GI

A PD-L1 debate among pathologists:
Emerging trends on PD-L1 testing in MIUC
and Upper GI cancers

Upper GI and CPS:
A Ping Pong game between
a Pathologist and an Oncologist

Product information

PD-L1 testing
overview for OPDIVO

Dosing schemes
OPDIVO in GI cancers

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

Patient brochure
with practical information
on immunotherapy

www.immunooncology.be

An educational website
on immunotherapy for your
nurses and your patients

Patient alert card
OPDIVO

Useful links

ImmunoScience Academy
An educational multi-disciplinary platform on immunology and immunotherapy

BSMO immunomanager Comprehensive recommendations
on the diagnostic algorithm and treatment of different types of irAE

Belgian Multidisciplinary Immunotoxicity Board (BITOX) Submit your case/questions
about irAEs

BSP poster
 PD-L1 testing
accross tumor indications

irAE(s), immune-related adverse event(s)

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.